New hope for tough prostate cancer: drug combo trial launches

NCT ID NCT07206056

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 31 times

Summary

This study tests a new combination of two drugs (tulmimetostat and JSB462) against standard care in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The trial has two parts: first finding the safest dose, then comparing the combo's effectiveness. About 188 men will take part worldwide.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutchinson Cancer Research Center

    RECRUITING

    Seattle, Washington, 98109-1024, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mass General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Email: •••••@•••••

    Contact

  • Novartis Investigative Site

    RECRUITING

    St Leonards, New South Wales, 2065, Australia

  • Novartis Investigative Site

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Novartis Investigative Site

    RECRUITING

    Liverpool, 2170, Australia

  • Novartis Investigative Site

    RECRUITING

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • Novartis Investigative Site

    RECRUITING

    Beijing, 100021, China

  • Novartis Investigative Site

    RECRUITING

    Herlev, DK-2730, Denmark

  • Novartis Investigative Site

    RECRUITING

    Odense C, 5000, Denmark

  • Novartis Investigative Site

    RECRUITING

    Vejle, DK-7100, Denmark

  • Novartis Investigative Site

    RECRUITING

    Bordeaux, 33076, France

  • Novartis Investigative Site

    RECRUITING

    Paris, 75015, France

  • Novartis Investigative Site

    RECRUITING

    Paris, 75231, France

  • Novartis Investigative Site

    RECRUITING

    Düsseldorf, North Rhine-Westphalia, 40225, Germany

  • Novartis Investigative Site

    RECRUITING

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    RECRUITING

    Padova, PD, 35128, Italy

  • Novartis Investigative Site

    RECRUITING

    Orbassano, TO, 10043, Italy

  • Novartis Investigative Site

    RECRUITING

    Kuching, Sarawak, 93586, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Poznan, 60-192, Poland

  • Novartis Investigative Site

    RECRUITING

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    RECRUITING

    Singapore, S308433, Singapore

  • Novartis Investigative Site

    RECRUITING

    Santiago Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28009, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28041, Spain

  • Novartis Investigative Site

    RECRUITING

    Sutton, Surrey, SM2 5PT, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    London, W1G 6AD, United Kingdom

  • Sarah Cannon Research Institute

    RECRUITING

    Denver, Colorado, 80218, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Sarah Cannon Research Institute

    RECRUITING

    Jacksonville, Florida, 32256, United States

    Contact Email: •••••@•••••

    Contact

  • Wichita Urology Group PA

    RECRUITING

    Wichita, Kansas, 67226, United States

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.